BW813U
BW813U is a blood-brain barrier-permeable choline acetyltransferase (ChAT) inhibitor. BW813U reduces acetylcholine secretion, decreases cancer cell viability, and slows tumor growth rate. BW813U alters reference memory and causes working memory dysfunction. BW813U shows a synergistic effect with age factors in memory deficits of rats. BW813U can be used in studies related to Alzheimer's disease and lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 774142-74-4
- Formula: C15H18ClNO
- Molecular Weight:263.76
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
BW813U potently reduces the viability of human SCC-L and LAC cell lines in vitro in a concentration-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
BW813U (2.5 mg/kg; i.p.; three times per week) potently reduces the growth rate of xenografted H838 human lung adenocarcinoma tumors in athymic mice without causing obvious toxicity[2].
BW813U (100 mg/kg; i.p.; single administration) causes a synergistic prolongation of peak latency in rats with increasing age, indicating impaired reference memory; it also eliminates memory retention of pre-gap signal duration in the PI-GAP test, indicating impaired working memory for temporal information[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 325-375 g at study start)[1]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg; 100 μM
-
Administration:i.p.; single injection; intracranial (bilateral); single injection
-
Result:Caused 60% decrease in cortex, 48% decrease in hippocampus, and 70% decrease in caudate nucleus ChAT activity 1 hour post-injection.
Caused a rapid decrease in ChAT activity, with 45% decrease in cortex and 55% decrease in hippocampus at day 1, persisting (with partial recovery) through day 19.
Caused 78% decrease in cortex, 68% decrease in hippocampus, and 85% decrease in caudate nucleus ChAT activity 1 hour post-injection.
Caused sustained ChAT inhibition for 1 week post-injection.
-
Animal Model:Athymic mice[2]
-
Dosage:2.5 mg/kg
-
Administration:i.p.; thrice a week
-
Result:Robustly decreased the growth rate of H838 human LAC tumors.
No gross toxicity, behavioral discomfort, or differences in body weight, food consumption, or water consumption were observed between BW813U-treated and vehicle-treated mice.
-
Animal Model:Charles River CD (male, mature: 6-10 months, ~400 g; aged: 26-30 months, ~400 g)[3]
-
Dosage:100 mg/kg
-
Administration:i.p.; single injection
-
Result:Increased mean peak time to 22.3 s in mature rats (vs 20.6 s in vehicle controls) in post-drug PI testing.
Increased mean peak time to 30.25 s in aged rats (vs 24.6 s in vehicle controls) in post-drug PI testing.
Increased mean peak time on gap trials by 15.8 s in mature rats (vs 6.0 s in vehicle controls) in post-drug PI-GAP testing.
Increased mean peak time on gap trials by 16.4 s in aged rats (vs 6.5 s in vehicle controls) in post-drug PI-GAP testing.
Showed no significant differences in peak rate and coefficient of variation measures compared to vehicle groups in post-drug PI testing.
Showed no significant differences in peak rate measures between probe trials with and without gaps.
Chemical Information
-
CAS No. 774142-74-4
-
Molecular Weight 263.76
-
Formula C15H18ClNO
-
SMILES
ClC1=CC=CC(/C=C/C2=NC(C)(C)CC(C)O2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
[1]. Wenk G, et al. Cholinergic function and memory: extensive inhibition of choline acetyltransferase fails to impair radial maze performance in rats. Pharmacol Biochem Behav. 1986;25(3):521-526. [Content Brief]
[2]. Friedman JR, et al. Acetylcholine signaling system in progression of lung cancers. Pharmacol Ther. 2019 Feb;194:222-254. [Content Brief]
[3]. Meck WH, et al. Temporal memory in mature and aged rats is sensitive to choline acetyltransferase inhibition. Brain Res. 2006;1108(1):168-175. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)